GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

By Nikhil Sharma (Reuters) -European shares dipped on Wednesday, as the rise in healthcare companies after Novo Nordisk's ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

European stocks remained flat in early trading Wednesday, as gains in healthcare were counterbalanced by a decline in ...

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...

Learn more about how GSK is harnessing the power of technology to improve outcomes for people with cancer.